Drug Discovery World

AUGUST 9, 2022

Provider to the life sciences industry BioIVT has acquired enzymes manufacturer Cypex in a bid to enhance its product portfolio. . This technology enables the expression of human drug-metabolizing enzymes in bacteria, without requiring large modifications to the proteins.? .

In-Vitro 52

In-Vitro Protein Production Bacteria 52

Drug Discovery World

SEPTEMBER 28, 2023

This is likely in part because their byproduct, lactic acid, is known to inhibit pathogenic bacteria 25. And, in the endometrium, a decrease in Lactobacillus may affect embryo attachment and promote the growth of detrimental bacteria. This article will focus on one such area of great unmet need and promise: women’s health.

Clinical Trials 64

Clinical Trials Clinical Trials Regulation Bacteria 64

XTalks

AUGUST 9, 2023

Xdemvy, specifically formulated as an ectoparasiticide (anti-parasitic) for Demodex blepharitis treatment, contains the active ingredient lotilaner, a member of the isoxazoline compound family. California-based Tarsus Pharmaceuticals Inc., Xdemvy is now authorized to treat Demodex blepharitis, offering a new option for affected patients.

FDA Approval 98

FDA Approval In-Vitro Trials Bacteria 98

XTalks

NOVEMBER 4, 2020

It has long been known that mothers greatly influence the development of the growing fetus by not only providing nutrients through the placenta, but also a growing list of biological elements including beneficial antibodies, gut bacteria and now, allergies. They reported their findings last week in the journal Science.

Allergies 98

Allergies Antibody In-Vitro Development 98